Jenna Gallegos
Freelance Contributor at Freelance
Devoted fan of food, beer, & all things science Director of Scientific Marketing @sambasci - Postdoc in #SynBio - PhD in plant #biotech
Articles
-
1 month ago |
synbiobeta.com | Jenna Gallegos
We’ve been thinking about probiotics all wrong. Typical probiotic supplements attempt to “seed” the microbiome—to shift the population of bugs in our gut in a predictable, favorable direction. The problem is, that approach just doesn’t work. Fortunately, there are a handful of biotech companies who are thinking differently. Probiotics of the future will look very different. They’ll be thoughtfully selected or engineered strains clinically proven to deliver particular benefits.
-
Jul 8, 2024 |
synbiobeta.com | Jenna Gallegos
Ten years ago, all anybody could talk about was big data. Suddenly, sequencing costs had plummeted, and there weren’t enough Python aficionados out there to analyze the mountains of sequencing data. This so-called “big data” problem was touted as the only thing standing between sequencing reads and curing cancer. At the SynBioBeta conference this year, a different problem emerged—a “small data” problem.
-
Apr 28, 2024 |
synbiobeta.com | Jenna Gallegos
We've all heard the analogies. Chopping up cells and analyzing them in bulk is like trying to pick up the taste of a single bad blueberry in a slurpy-sized fruit smoothy. Single-cell analysis is important and essential for studying rare cell populations that play important roles in cancer and immunology. But it's also expensive and technically challenging. We've also heard the phrase send a thief to catch a thief, a spy to catch a spy. Well, what if we could send a cell to catch a cell?
-
Mar 11, 2024 |
synbiobeta.com | Jenna Gallegos
As the annual SynBioBeta event approaches, the industry is grappling with fewer funding opportunities and shorter runways—leading innovators to focus their efforts on the most robust of industries: healthcare. With the pharmaceutical industry grappling with high failure rates and a surplus of "me-too" drugs, the integration of Artificial Intelligence (AI) into synthetic biology processes offers promising solutions.
-
Jan 1, 2024 |
synbiobeta.com | Jenna Gallegos
Despite your painstaking efforts to pick perfect produce, you didn’t notice the tiny bit of mold growing on that one strawberry on your weekend grocery stock-up. By Friday, you’ve got a full-on fuzz fest on your hands. Fungus spreads fast, even in your fridge. And your mushy strawberries were the lucky ones. Plenty of their neighbors died in the field, never to produce a fruit.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 2K
- DMs Open
- Yes
In this webinar, you'll learn to: 1) Define your marketing goals 2)Translate revenue goals into marketing KPIs 3) Set realistic budgets 4) Report on marketing performance relative to goals/budget Register here for free: https://t.co/HXzuGSlayS https://t.co/wD4yUQabJe
Free webinar tomorrow to help #Biotechnology companies decide when to invest in marketing and how to make the most of their budgets. Tune in and say hi if you're free! https://t.co/HXzuGSlayS
Internet in 1999 = 100 billiom words. LLM training data = 200 billion words. DNA encodes trillions of amino acid combinations. That's a lot of data. #synbio2024 #MachineLearning #ArtificialIntelligence